Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (705)	4/8/1999 9:10:00 PM
From: M. P. McNamara, Jr. M.D.	Read Replies (1) \| Respond to of 2001

The good news of yesterday's announcement was too quickly overshadowed. For those who are inclined to visit a medical library, the company's press release was about Volume 21, Supplement 1 of the journal Neurological Research. The focus of the entire issue (11 papers and an editorial overview) is epidural fibrosis, its clinical significance and the invaluable role of Adcon-L in controlling it. As a physician, I enjoyed all of the papers and found them instructive. As an investor in Gliatech, I was overjoyed to see further documentation supporting prophylactic use of Adcon-L. The editor, Jacques Brotchi, M.D., Ph.D., in the introductory overview states “Our medical experience with Adcon-L has been considerable both in primary surgical cases, and in cases of re-operation. Today, Adcon-L is routinely used in our practice.” I can foresee a time, in the not too distant future, where a physician will have to explain why he (or she) did not use Adcon-L. “Standard of Care” here we come. Note: I also posted this on the Yahoo GLIA board as well. Actually, I posted it last evening and Yahoo lost it (as well as about 10 other posts last night).

To: scaram(o)uche who wrote (705)	4/9/1999 2:05:00 AM
From: Asymmetric	Read Replies (1) \| Respond to of 2001

Hopefully whichever fund is dumping is finished. Drying up of volume today was encouraging as was the small recovery in the stock. It's much easier to remain steadfast in one's holdings when one sees the quality of the people like yourself, Richard, and Dr McNamara holding firm -- and when the medical literature also tells us in no uncertain terms that we are all on the right track here. MACD looks about as negative as it's going to get here after having been on a long extended decline. I may be wrong, but technically, I say we go up from here. This stock is simply oversold and many nervous nellies got cleared out when the stock hit $18 and change yesterday. Can't see where there's that many sellers left...not at this price anyway. Dr McNamara: Thanks for the pointer to the neurological research journal. I don't work far from a university with a medical school and since I have to work this weekend, I'll drop by afterward with a pocketful of change and copy some of the articles to read. Peter.